UPDATE 1-Nestle invests $200 mln more in Aimmune after peanut allergy drug approval
February 05, 2020 at 09:09 AM EST
Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million in the drugmaker, bringing the Swiss company's total investment to $473 million.